Know Cancer

forgot password

Randomized Multicentric Phase II Study of Prolonged Adjuvant Temozolomide or "Stop and Go" in Glioblastoma Patients: The PATSGO Study

Phase 2
18 Years
Open (Enrolling)

Thank you

Trial Information

Randomized Multicentric Phase II Study of Prolonged Adjuvant Temozolomide or "Stop and Go" in Glioblastoma Patients: The PATSGO Study


Inclusion Criteria:

1. Patients with histologically confirmed diagnosis of GBM

2. Availability of pre-treatment GBM tissue to determine the activation status of MGMT
gene is not mandatory but strongly recommended

3. Patients must have received radiation and TMZ for 6 weeks followed by 6 months of
TMZ. Randomization should be performed within the 6 weeks after the last

4. A brain MRI with or without a PET-Scan-methionine must be performed before enrolment.

5. Age ≥ 18 years

6. Karnofsky Performance status ≥ 60

7. Normal haematological functions: ANC ≥ 1.5 x 109cells/l, platelets ≥ 100 x 109

8. Normal liver function: total bilirubin < 1.5 x ULN, alkaline phosphatase and
transaminases (ASAT/ALAT) < 2.5 times the upper limit of the normal range

9. Serum creatinine < 1.5 x ULN

10. Clinically normal cardiac function without history of ischemic heart disease in the
past 12 months. Absence of cardiac insufficiency NYHA grade III and IV, instable
angina, arrhythmia

11. No previous or current malignancy (except treated basal or squamous cell skin
carcinoma, cervix cancer or in situ carcinoma of the breast).

12. All patients (male and female) with reproductive potential must use effective
contraception. Females must have a negative serum pregnancy test at entry to study.

13. Signed informed consent from the patient or legal representative must be obtained.

Exclusion Criteria:

All non inclusion criteria

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

to determine whether prolonged administration of Temozolomide in glioblastoma patients increase their progression-free and overall survival at 6 months

Outcome Time Frame:

36 months

Safety Issue:


Principal Investigator

Jean-Francois Baurain, MD, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Cliniques universitaires Saint-Luc


Belgium: Federal Agency for Medicinal Products and Health Products

Study ID:

UCL-ONCO 06-004



Start Date:

January 2008

Completion Date:

January 2012

Related Keywords:

  • Glioblastoma
  • Temozolomide
  • Phase II
  • Chemotherapy
  • Glioblastoma
  • Progression-free Survival
  • Glioblastoma